natgillin/translations-raw huggingface dataset:
A developer supply container according to Claim 3 or 4, wherein the developer in said developer supply container has a fluidity energy of not less than 4.3x 10-4 kg.cm2/s2 and not more than 4.14x 10-3 kg.cm2/s2, and wherein said discharge opening has an area not more than 12.6 mm2. 
Spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 - 4, nadalje sadrži razvijač, pri čemu razvijač u navedenom spremniku za nadopunjavanje (1) ima energiju fluidnosti ne manju od 4.3x 10-4 kg.cm2/s2 i ne veću od 4.14x 10-3 kg.cm2/s2, i pri čemu navedeni otvor za pražnjenje (3a) ima površinu ne veću od 12.6 mm2.
A developer supply container according to any one of Claims 1 - 6, wherein said drive converting portion converts the rotational force so that said pump portion reciprocates a plurality of times per one full rotation of said feeding portion. 
Spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 - 6, pri čemu navedeni dio za pretvaranje pogona (2d, 3b) pretvara rotacijsku silu tako da navedeni dio za ubrizgavanje (2b) reciprocira više puta tijekom jedne pune rotacije opskrbnog dijela (2c).
A compound according to claim 1, for the use in the treatment of diseases or disorders selected from hypercholesterolemia, hyperlipoproteinemia, hypertri-glyceridemia, dyslipidemia, lipodystrophy, cholestasis/fibrosis, cholesterol gallstone disease, gastrointestinal disease or condition, hyperglycemia, diabetes mellitus, type 2 diabetes, insulin resistance, metabolic inflexibility, nephropathy, liver diseases, atherosclerosis, cancer, inflammatory disorders, obesity, osteoporosis, skin aging, hair growth regulation and pigmentation disorders, Parkinson's disease and/or Alzheimer's disease. 
Spoj prema zahtjevu 1, naznačen time da je za uporabu kod liječenja bolesti ili poremećaja odabranih od hiperkolesterolemije, hiperlipoproteinemije, hipertrigliceridemije, dislipidemije, lipodistrofije, kolestaze/fibroze, žučnih kamenaca kao posljedice taloženja kolesterola, gastrointestinalne bolesti ili stanja, hiperglikemije, dijabetes melitusa, dijabetesa tipa 2, inzulinske rezistencije, metaboličke nefleksibilnosti, nefropatije, bolesti jetre, ateroskleroze, raka, upalnih poremećaja, pretilosti, osteoporoze, starenja kože, regulacije rasta kose i poremećaja pigmentacije, Parkinsonove bolesti i/ili Alzheimerove bolesti.
a first toothed wheel (11) comprising first inclined teeth (12) extending in a generally radial direction, 
prvi zupčanik (11) s prvim kosim zupcima (12) koji se pružaju u općenito radijalnom smjeru,
in a first engaging position in which a first pawl end (41) engages with the first toothed wheel (11) which allows the respective actuators to actuate the first toothed wheel (11) in the first rotating direction, and 
u prvom zahvatnom položaju u kojem prvi kraj zaponca (41) zahvaća prvi zupčanik (11) čime je omogućeno da odgovarajući aktuatori pokreću prvi zupčanik (11) u prvom smjeru rotacije, i
Reversible rotation mechanism according to claim 1, wherein the actuators (31-34) are linear actuators which are positioned along the circumference of the first and second toothed wheels (11, 21) arranged to perform a linear stroke substantially tangentially to the circumference of the first and second toothed wheels (11, 21). 
Reverzibilni rotacijski mehanizam prema zahtjevu 1, gdje su aktuatori (31-34) linearni aktuatori koji su smješteni duž oboda prvog i drugog zupčanika (11, 21) i raspoređeni da odrađuju linearni udar u biti tangencijalno na obod prvog i drugog zupčanika (11, 21).
Reversible rotation mechanism according to claim 6, wherein the first and second subsets actuate the first or second toothed wheels (11, 21) in turns. 
Reverzibilni rotacijski mehanizam prema zahtjevu 6, gdje prvi i drugi podset pokreću prvi ili drugi zupčanik (11, 21) naizmjence.
Reversible rotation mechanism according to any one of the preceding claims, wherein the two-ended pawls (40) are connected to the respective actuators (31 - 34) via a hinged connection member (36). 
Reverzibilni rotacijski mehanizam prema bilo kojem od prethodnih zahtjeva, gdje su zaponci s dva kraja (40) spojeni za odgovarajuće aktuatore (31 - 34) preko zglobnog spojnog člana (36).
in the first lock state the lock (50) prevents the two-ended pawl (40) from reaching the second engaging position and 
u prvom stanju zaključavanja brava (50) sprječava da zaponac s dva kraja (40) dođe u drugi zahvatni položaj i
in the second lock state the lock (50) prevents the two-ended pawl (40) from reaching the first engaging position. 
u drugom stanju zaključavanja brava (50) sprječava da zaponac s dva kraja (40) dođe u prvi zahvatni položaj.
Vessel according to claim 15, wherein the vessel comprises at least one superstructure integrated with the reversible rotation mechanism (1) or discharge assembly (100). 
Plovilo prema zahtjevu 15, gdje plovilo ima barem jednu superstrukturu integriranu s reverzibilnim rotacijskim mehanizmom (1) ili izbačajnim sklopom (100).
a developer discharging chamber (3h) provided with a discharge opening (3e) configured to permit discharging of the developer fed by said feeding portion (2c); and 
komore za pražnjenje razvijača (3k) opremljene otvorom za pražnjenje (3e) za omogućavanje pražnjenja razvijača nakon što je opskrbljen navedenim opskrbnim dijelom (2c);
A developer supply container according to Claims 1 or 2, wherein said drive converting portion (2d, 3b) converts the rotational force so that an internal pressure of said developer discharging chamber (3h) changes between a pressure lower than an ambient pressure and a pressure higher than the ambient pressure. 
Spremnik za nadopunu razvijača (1) sukladno Zahtjevima 1 ili 2, gdje navedeni dio za pretvaranje pogona (2d, 3b) pretvara rotacijsku silu tako da se unutarnji pritisak barem navedene komore za pražnjenje razvijača (3h) mijenja između pritiska nižeg od pritiska okoline i pritiska višeg od pritiska okoline s resiprocitetom navedenog dijela za ubrizgavanje (2b).
A developer supply container (1) according to Claim 3, wherein with increase of a volume of a chamber of said pump portion (2b), the pressure at least in said developer discharging chamber (3h) becomes negative. 
Spremnik za nadopunu razvijača (1) sukladno Zahtjevu 1, pri čemu s povećanjem volumena komore navedenog dijela za ubrizgavanje (2b), pritisak barem u navedenoj komori za pražnjenje razvijača (3h) postaje negativan.
A developer supply container according to Claims 3 or 4, furthermore comprising a developer, wherein the developer in said developer supply container (1) has a fluidity energy of not less than 4.3x 10-4 kg.m2/s2 and not more than 4.14x 10-3 kg.m2/s2, and wherein said discharge opening (3a) has an area not more than 12.6 mm2. 
Spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 - 4, nadalje sadrži razvijač, pri čemu razvijač u navedenom spremniku za nadopunjavanje (1) ima energiju fluidnosti ne manju od 4.3x 10-4 kg.cm2/s2 i ne veću od 4.14x 10-3 kg.cm2/s2, i pri čemu navedeni otvor za pražnjenje (3a) ima površinu ne veću od 12.6 mm2.
A developer supply container according to any one of Claims 1 - 5, wherein said drive converting portion (2d, 3b) converts the rotational force such that a suction action and a delivery action are alternately carried out through said discharge opening (3a) with the reciprocation of said pump portion (2b). 
Spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 - 5, pri čemu navedeni dio za pretvaranje pogona (2d, 3b) pretvara rotacijsku silu tako da su postupci uvlačenja i ispuštanja izmjenično provedeni kroz navedeni otvor za pražnjenje (3a) s reciprocitetom s navedenim dijelom za ubrizgavanje (2b).
A developer supply container (1) according to any one of Claims 1 - 6, wherein said drive converting portion (2d, 3b) converts the rotational force so that said pump portion (2b) reciprocates a plurality of times per one full rotation of said feeding portion (2c). 
Spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 - 6, pri čemu navedeni dio za pretvaranje pogona (2d, 3b) pretvara rotacijsku silu tako da navedeni dio za ubrizgavanje (2b) reciprocira više puta tijekom jedne pune rotacije opskrbnog dijela (2c).
A developer supply container according to Claim 19, wherein said nozzle portion (47) is provided with a plurality of openings (51) around a free end side thereof. 
Spremnik za nadopunu razvijača sukladno Zahtjevu 17, pri čemu navedeni dio s mlaznicom (47) sadrži više otvora (51) oko slobodne strane iste.
a feeding portion (2c) for feeding the developer in said developer accommodating chamber (2, 2k) with rotation thereof; and a gear portion (2a) configured and positioned to receive a rotational force for rotating said feeding portion (2c); 
komore za prilagodbu razvijača (2k) za prilagođavanje razvijača; i opskrbnog dijela (2c) za opskrbu razvijača u navedenoj komori za prilagodbu razvijača(2k) s rotacijom opskrbnog dijela (2c);
A developer supply container according to claim 9, wherein said nozzle portion (47) is provided with a plurality of further openings (51) around a free end side thereof. 
Spremnik za nadopunu razvijača sukladno Zahtjevu 17, pri čemu navedeni dio s mlaznicom (47) sadrži više otvora (51) oko slobodne strane iste.
two separable fastenable neck bands (1) which are part of the serviette and provided by longitudinal perforations at two opposites sides of the serviette and can be optionally partly separated from the serviette; 
dvije odvojive pričvrsne vratne trake (1) koje su dio salvete i koje imaju uzdužne perforacije na dvije suprotne strane salvete i koje se mogu po želji djelomično odvojiti od salvete;
Serviette of claim 1, characterised in that the shape of the bands (1) can be slightly conical. 
Salveta iz patentnog zahtjeva 1., naznačena time da oblik traka (1) može biti blago koničan.
each heteroaryl is independently (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, or (ii) a 9- or 10-membered heterobicyclic, fused ring system containing from 1 to 6 heteroatoms independently selected from N, O and S, wherein either one or both of the rings contain one or more of the heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2; 
svaki heteroaril je nezavisno (i) 5- ili 6-člani heteroaromatičan prsten koji sadrži od 1 do 4 heteroatoma nezavisno izabrana od N, O i S, pri čemu je svaki N izborno u obliku oksida, ili (ii) 9- ili 10-člani heterobicikličan, fuzionirani sustav prstena koji sadrži od 1 do 6 heteroatoma nezavisno izabranih od N, O i S, pri čemu bilo koji ili oba prstena sadrže jedan ili više heteroatoma, najmanje jedan prsten je aromatičan, svaki N je izborno u obliku oksida, i svaki S u prstenu koji nije aromatičan je izborno S(O) ili S(O)2;
and X2 are each independently: 
i X2 su svaki nezavisno:
A compound of Formula I according to claim 1, wherein the compound is selected from the group consisting of: and pharmaceutically acceptable salts thereof. 
Spoj formule I prema patentnom zahtjevu 1, gdje je spoj izabran iz grupe koju čine: [image] [image] i njegove farmaceutski prihvatljive soli.
A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži efikasnu količinu spoja prema bilo kojem od patentnih zahtjeva 1-10, ili njegove farmaceutski prihvatljive soli, i farmaceutski prihvatljiv nosač.
A pharmaceutical composition comprising an effective amount of the compound according to claim 10 and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži efikasnu količinu spoja prema patentnom zahtjevu 10 i farmaceutski prihvatljiv nosač.
The compound according to claim 10 for use in the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof. 
Spoj prema patentnom zahtjevu 10 za upotrebu u profilaksi ili tretmanu infekcije HIV-om ili za profilaksu, tretman ili odgađanje početka SIDA-e kod subjekta kod kojeg postoji potreba za tim.
A nozzle (101) for applying a lining material onto an inner surface of a pipe to create a lining in the pipe, comprising: 
Mlaznica (101) za nanošenje materijala za unutarnje oblaganje na unutarnju površinu cijevi kako bi nastala unutarnja obloga u cijevi, sadrži:
A nozzle (101) according to claim 1, wherein the first outlet portion (411b, 511b, 911b) is larger than the second outlet portion (411a, 511a, 911a). 
Mlaznica (101) sukladno Zahtjevu 1, pri čemu je prvi izlazni dio (411b, 511b, 911b) veći od drugog izlaznog dijela (411a, 511a, 911a).
A nozzle (101) according to claim 1, wherein said distribution members (104) are connected to an end member (110) arranged at an end of the circumferentially and axially extending surface, the end member being arranged to enclose a portion of said surface. 
Mlaznica (101) sukladno Zahtjevu 1, pri čemu su navedeni distribucijski članci (104) povezani s krajnjim člankom (110) organizirani na kraju cirkumferentno i aksijalno protežuće površine, krajnji članak postavljen je tako da zatvara dio navedene površine.
A nozzle (101) according to any of claims 1-3, wherein each distribution member (104, 1204, 1304, 1404) comprises a first portion (104') and a second portion, said first portion leading the second portion during rotation of the distribution member. 
Mlaznica (101) sukladno bilo kojem od Zahtjeva 1-3, pri čemu svaki distribucijski članak (104, 1204,1304,1404) sadrži prvi dio (104') i drugi dio, navedeni prvi dio vodi drugi dio tijekom rotacije distribucijskog članka.
A nozzle (101) according to claim 4, wherein the first portion (104') is arranged closer to the radially inner space (107) than the second portion. 
Mlaznica (101) sukladno Zahtjevu 4, pri čemu je prvi dio (104') postavljen bliže radijalnom unutarnjem prostoru (107) od drugog dijela.
A nozzle (101) according to claim 4, wherein first portion (104') is arranged closer to an axial end of the radially inner space (107) than the second portion. 
Mlaznica (101) sukladno Zahtjevu 4, pri čemu je prvi dio (104') postavljen bliže aksijalnom kraju radijalnog unutarnjeg prostora (107) od drugog dijela.
A nozzle (101) according to any of the preceding claims, wherein each distribution member (104, 1204, 1304, 1404) comprises a surface for receiving lining material leaving the radially inner space, the surface extending in an axial and radial direction and facing in the rotational direction of the distribution member. 
Mlaznica (101) sukladno bilo kojem od prethodnih Zahtjeva, pri čemu svaki distribucijski članak (104, 1204, 1304, 1404) ima površinu za primanje materijala za oblaganje ostavljajući radijalni unutarnji prostor, površina se proteže u radijalnom i aksijalnom smjeru i sučelice rotacijskom smjeru distribucijskog članka.
A nozzle (101) according to claim 8, wherein the surface of each distribution member (104) extends from a radially inner edge to a radially outer edge, wherein the nozzle is arranged such that lining material released from each distribution member passes said radially outer edge. 
Mlaznica (101) sukladno Zahtjevu 8, pri čemu se površina svakog distribucijskog članka (104) proteže od radijalnog unutarnjeg ruba prema radijalnom vanjskom rubu, pri čemu je mlaznica postavljena tako da materijal za oblaganje ispušten iz svakog distribucijskog članka prolazi navedeni radijalni vanjski rub.
A nozzle (101) according to any of the preceding claims, further comprising a plurality of outlet portions (111a, 111b, 111c, 111a', 111b', 111c') arranged such that the more than one distribution members (104) during a full rotation about the radially inner space simultaneously covers only a subset of said plurality of outlet portions. 
Mlaznica (101) sukladno bilo kojem od prethodnih Zahtjeva, koja nadalje sadrži više izlaznih dijelova (111a, 111b, 111c, 111a’, 111b’, 111c’) organiziranih tako da više od jednog distribucijskog članka (104) prilikom pune rotacije oko radijalnog unutarnjeg prostora istovremeno pokriva samo podskupinu od navedenih više izlaznih dijelova.
through R5 are as defined above; and 
do R5 su kako je gore definirano; i
Liquid ring pump according to claim 1, characterised in that the outlet chamber (17) is provided with an axial vane (40) extending over a part of the length of the drive shaft (16) in the outlet chamber (17) in the direction of the flow of sewage. 
Pumpa sa tekućim prstenom sukladno zahtjevu 1, naznačena time da je izlazna komora (17) snabdjevena aksijalnom lopaticom (40), koja se pruža preko dijela pogonske osovine (16) u izlaznoj komori (17) u smjeru protoka otpadnih voda.
Liquid ring pump according to claim 1, characterised in that the outlet chamber (17) is provided with a radial vane (50) extending around a part of the drive shaft (16) in the outlet chamber (17) in the direction of the flow of sewage. 
Pumpa sa tekućim prstenom sukladno zahtjevu 1, naznačena time da je izlazna komora (17) snabdjevena radijalnom lopaticom (50), koja se pruža oko dijela pogonske osovine (16) u izlaznoj komori (17) u smjeru protoka otpadnih voda.
Liquid ring pump according to claim 1, characterised in that the pump inlet (11) is provided with a back-flow valve means (12). 
Pumpa sa tekućim prstenom sukladno zahtjevu 1, naznačena time da je ulazni otvor pumpe (11), izveden sa nepovratnim ventilom (12).
Method according to claim 8, characterised in that the flow of sewage is directed along and towards the mechanical seal (20) as the flow of sewage is pumped into and through the outlet chamber (17) towards the integrated extension (18) and the pump outlet (19). 
Postupak sukladno zahtjevu 8, naznačen time da je tok otpadnih voda usmjeren uzduž i prema mehaničkoj brtvi (20), kao što se tok otpadnih voda pumpa u i kroz izlaznu komoru (17) prema integriranom nastavku (18) i izlaznom otvoru pumpe(19).
Method according to claim 8, characterised in that the flow of sewage is directed around and towards the mechanical seal (20) as the flow of sewage is pumped into and through the outlet chamber (17) towards the integrated extension (18) and the pump outlet (19). 
Postupak sukladno zahtjevu 8, naznačen time da je tok otpadnih voda usmjeren okolo i prema mehaničkoj brtvi (20) kao što se tok otpadnih voda pumpa u i kroz izlaznu komoru (17) prema integriranom nastavku(18) i izlaznom otvoru pumpe (19).
Method according to claim 8, characterised in that the flow of sewage is obstructed and retained by a flange means (181) arranged in the integrated extension (18) of the outlet chamber (17) before the flow of sewage is discharged from the pump outlet (19). 
Postupak sukladno zahtjevu 8, naznačen time da se protok otpadnih voda sprječava i zadržava prirubnicom (181) postavljenom u integriranom nastavku (18) izlazne komore (17), prije ispuštanja toka otpadnih voda iz izlaznog otvora pumpe (19).
Method according to claim 8, characterised in that solid components in the flow of sewage are macerated by means of a macerator device (30) upstream of the pump housing (14). 
Postupak sukladno zahtjevu 8, naznačen time da su krute komponente u protoku otpadnih voda usitnjene pomoću mehanizma za usitnjavanje (30), koji se nalazi ispred kućišta pumpe (14).
A compound that has the structure of Formula (XII): wherein, 
Spoj koji ima strukturu prema Formuli (XII):
A method of decoding video, the method comprising: 
Uređaj za dekodiranje video slike, uređaj sadrži:
The pharmaceutical composition for use as claimed in claim 1, wherein the method of therapy is a method of treatment or prevention of a cancer characterized by expression of the tumor-associated antigen according to claim 1, in which the cancer is preferably an esophageal tumor, an ovarian tumor, a head-neck tumor, a kidney tumor, a liver tumor, a lung tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, a stomach cancer, a pancreatic tumor, a renal cell carcinoma, a colon carcinoma or a mammary carcinoma. 
Farmaceutska kompozicija za primjenu prema zahtjevu 1, gdje je terapeutska metoda metoda liječenja ili prevencije raka, naznačeno time da je ekspresija antigena povezanog s tumorom prema zahtjevu 1, pri čemu je rak tumor jednjaka, tumor jajnika, tumor glave-vrata, tumor bubrega, tumor jetre, tumor pluća, tumor dojke, tumor prostate, tumor kolona, tumor želuca, rak želuca, tumor pankreasa, karcinom bubrežnih ćelija, karcinom kolona ili karcinom mliječnih žlijezda.
a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains; 
protutijelo u punoj duljini, koje se specifično veže na prvi antigen i sastoji se od dva jaka lanca protutijela i dva slaba lanca protutijela;
a polypeptide consisting of 
polipeptid koji se sastoji od sljedećih:
a polypeptide consisting of 
polipetid koji se sastoji od sljedećih:
and wherein the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) together form an antigen-binding site specifically binding to a second antigen. 
i pritom varijabilna domena jakog lanca protutijela (VH) od polipeptida pod točkom b) i varijabilna domena slabog lanca protutijela (VL) od polipeptida pod točkom c), zajedno tvore mjesto vezanja antigena, gdje se specifično vežu na drugi antigen.
wherein said interface is altered to promote the formation of the trivalent, bispecific antibody, wherein the alteration is characterized in that: 
pri čemu se navedeno sučelje mijenja u svrhu pokretanja tvorbe trovalentnog, bispecifičnog protutijela, gdje je ta promjena naznačena time, da se
The trivalent, bispecific antibody according to claim 4, characterized in that the CH3 domain under i) comprises Y349C, T366W mutations; and the CH3 domain under ii) comprises S354C, T366S, L368A, Y407V mutations. 
Trovalentno, bispecifično protutijelo prema zahtjevu 4, naznačeno time, da CH3-domena pod točkom i) sadrži mutacije: Y349C, T366W; i CH3-domena pod točkom ii) sadrži mutacije: S354C, T366S, L368A, Y407V.
A pharmaceutical composition comprising a trivalent, bispecific antibody according to claims 1 to 9. 
Farmaceutski sastav, naznačen time, da obuhvaća trovalentno, bispecifično protutijelo prema zahtjevima od 1 do 9.
A nucleic acid encoding a trivalent, bispecific antibody according to claim 1 to 9. 
Nukleinska kiselina, naznačena time, da kodira trovalentno, bispecifično protutijelo prema zahtjevima od 1 do 9.
The method of claim 1, wherein Cmax of the recombinant human LAL is about 200 ng to about 800 ng per mL of serum. 
Rekombinantna humana LAL za uporabu prema zahtjevu 1, naznačena time, da je spomenuta primjena dovoljna za postizanje Cmax od 200 ng/mL do 800 ng/mL.
an effective amount of a compound having the formula: wherein Z is phenyl substituted with from 1 to 5 halogens chosen from fluorine and chlorine; 
djelotvornu količinu spoja s formulom: [image], gdje je Z fenil, supstituiran s od 1 do 5 halogena, koje se bira između fluora i klora;
one or more chemotherapeutic agents. 
jedno ili više kemoterapijskih sredstava.
An expanded polystyrene particle provided on the surface thereof with a skin layer with superior moldability wherein the skin layer comprises a binder selected from the group consisting of a thermoplastic resin-based adhesive, a thermosetting resin-based adhesive, an inorganic adhesive, a protein-based adhesive and a mixture thereof, wherein the skin layer further comprises methylene diphenyl diisocyanate. 
Čestica ekspandiranog polistirena koja na svojoj površini ima površinski sloj sa superiornim mogućnostima oblikovanja, naznačena time što površinski sloj sadrži vezivo koje se bira iz skupine koju čine ljepilo na bazi termoplastične smole, ljepilo na bazi duroplastične smole, anorgansko ljepilo, ljepilo na bazi proteina i njihova smjesa, gdje površinski sloj dodatno sadrži metilen-difenil-diizocijanat.